Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMRA Comera Life Sciences	$0.00	$0.00	$0.00 ▼ $0.03	$6K	1.28	6,565 shs	N/A
ETAO ETAO International	$0.00	$2.99	$1.70 ▼ $22.00	$2K	1.92	248,920 shs	75 shs
GNCA Genocea Biosciences		$0.00	$0.00 ▼ $0.00	$6K	1.61	83,499 shs	N/A
GNCAQ Genocea Biosciences		$0.00	$0.00 ▼ $0.00	$6K	1.74	1,863 shs	N/A

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMRA Comera Life Sciences	0.00%	0.00%	0.00%	+100.00%	-99.10%
ETAO ETAO International	0.00%	0.00%	0.00%	0.00%	-99.16%
GNCA Genocea Biosciences	0.00%	0.00%	0.00%	0.00%	+150.00%
GNCAQ Genocea Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMRA Comera Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETAO ETAO International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GNCAQ Genocea Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMRA Comera Life Sciences	N/A	N/A	N/A
ETAO ETAO International	N/A	N/A	N/A
GNCA Genocea Biosciences	N/A	N/A	N/A
GNCAQ Genocea Biosciences	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMRA Comera Life Sciences	$1.00M	0.01	N/A	N/A	N/A	∞
ETAO ETAO International	$58.89M	0.00	N/A	N/A	($16.96) per share	0.00
GNCA Genocea Biosciences	$1.91M	0.00	N/A	N/A	$0.47 per share	0.00
GNCAQ Genocea Biosciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMRA Comera Life Sciences	-$18M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ETAO ETAO International	-$896.68M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
GNCA Genocea Biosciences	-$33.20M	-$0.61	N/A	N/A	N/A	N/A	-182.88%	-62.76%	N/A
GNCAQ Genocea Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMRA Comera Life Sciences	N/A	N/A	N/A	N/A	N/A
ETAO ETAO International	N/A	N/A	N/A	N/A	N/A
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	N/A
GNCAQ Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMRA Comera Life Sciences	N/A	N/A	N/A
ETAO ETAO International	N/A	N/A	N/A
GNCA Genocea Biosciences	0.24	1.35	1.35
GNCAQ Genocea Biosciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMRA Comera Life Sciences	N/A
ETAO ETAO International	0.22%
GNCA Genocea Biosciences	0.64%
GNCAQ Genocea Biosciences	N/A

Insider Ownership

Company	Insider Ownership
CMRA Comera Life Sciences	8.90%
ETAO ETAO International	20.80%
GNCA Genocea Biosciences	1.61%
GNCAQ Genocea Biosciences	1.61%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMRA Comera Life Sciences	2	30.74 million	28.00 million	Not Optionable
ETAO ETAO International	3,600	5.12 million	4.06 million	Not Optionable
GNCA Genocea Biosciences	70	58.73 million	57.79 million	Not Optionable
GNCAQ Genocea Biosciences	70	58.73 million	N/A	Not Optionable

ETAO, CMRA, GNCA, and GNCAQ Headlines

Recent News About These Companies

Microbix Biosystems Inc. (MBXBF)

July 25, 2024 | finance.yahoo.com

Genocea Bio (GNCAQ) Earnings Dates & Reports

August 19, 2023 | investing.com

Genocea Biosciences Inc (GNCAQ)

August 11, 2023 | uk.investing.com

GNCAQ - Genocea Biosciences, Inc.

June 1, 2023 | ca.finance.yahoo.com

ETAO, CMRA, GNCA, and GNCAQ Company Descriptions

Comera Life Sciences NASDAQ:CMRA

$0.0002 0.00 (0.00%)

As of 08/8/2025

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

ETAO International NASDAQ:ETAO

ETAO International Co., Ltd., a digital healthcare company, provides medical care services. It develops healthcare ecosystem that consist online telemedicine, artificial intelligence, big data evaluation, online insurance, pharmacy, biotech, offline hospitals, and specialty clinics services. The company was incorporated in 2020 and is based in New York, New York.

Genocea Biosciences NASDAQ:GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Genocea Biosciences NASDAQ:GNCAQ

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time